Economic burden and loss of quality of life from dry eye disease in Canada.
| Autor: | Chan C; Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada., Ziai S; University of Ottawa Eye Institute, Ottawa, Ontario, Canada., Myageri V; IQVIA Solutions Canada Inc, Kirkland, Quebec, Canada., Burns JG; Novartis Pharmaceuticals Canada Inc, Dorval, Quebec, Canada., Prokopich CL; Optometry & Vision Science, University of Waterloo, Waterloo, Ontario, Canada. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | BMJ open ophthalmology [BMJ Open Ophthalmol] 2021 Sep 15; Vol. 6 (1), pp. e000709. Date of Electronic Publication: 2021 Sep 15 (Print Publication: 2021). |
| DOI: | 10.1136/bmjophth-2021-000709 |
| Abstrakt: | Objective: To describe the direct and indirect cost estimates of dry eye disease (DED), stratified by disease severity, and the impact of DED on quality of life (QoL) in Canadian patients. Methods and Analysis: A prospective, multicentre, observational, cross-sectional study was conducted at six sites across Canada. Eligible patients completed a 20 min survey on demography, general health, disease severity, QoL and direct (resource utilisation and out-of-pocket expenses for the past 3-24 months) and indirect costs (absenteeism and presenteeism based on Work Productivity and Activity Impairment questionnaire responses). Subgroup analyses were performed according to DED severity and presence of Sjögren's syndrome. Results: Responses from 146 of 151 participants were included in the analysis. DED was rated as moderate or severe by 19.2% and 69.2% of patients, respectively. Total mean annual costs of DED were $C24 331 (Canadian dollars) per patient and increased with patient-reported disease severity. Mean (standard deviation [SD]) indirect costs for mild, moderate and severe disease were $C5961 ($C6275), $C16 525 ($C11 607), and $C25 485 ($C22,879), respectively. Mean (SD) direct costs were $C958 ($C1216), $C1303 ($C1574) and $C2766 ($C7161), respectively. QoL scores were lowest in patients with Sjögren's syndrome (8.2% of cohort) and those with severe DED. Conclusion: This study provides important insights into the negative impact of DED in a Canadian setting. Severe DED was associated with higher direct and indirect costs and lower QoL compared with those with mild or moderate disease. Increased costs and poorer QoL were also evident for patients with DED plus Sjögren's syndrome versus DED alone. Competing Interests: Competing interests: CC has been a consultant for Alcon, Allergan, Bausch+Lomb, Johnson & Johnson, Labtician, Santen, and Shire* and has received research support from Allergan, Bausch+Lomb and TearLab. SZ has received grant/research support from Shire* and honoraria/consulting fees from Allergan, Labtician, J&J, Santen, and Shire*. VM was a paid consultant to Shire* in connection with this study. JGB was an employee of Shire* at the time of the study and is a current employee of Novartis. CLP has been a consultant for Alcon Canada, Innova Medical, Shire*, Novartis and Bausch+Lomb Canada. *A Takeda company. (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|